trending Market Intelligence /marketintelligence/en/news-insights/trending/2_xejd5hsyybupjbtsrahw2 content esgSubNav
In This List

United Therapeutics, MannKind complete licensing deal for blood pressure drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


United Therapeutics, MannKind complete licensing deal for blood pressure drug

United Therapeutics Corp. completed its licensing and collaboration agreement with MannKind Corp. to globally develop and commercialize a hypertension drug.

The agreement, which was cleared under U.S. antitrust laws Oct. 15, will see United Therapeutics develop a dry powder formulation of treprostinil that will be marketed worldwide.

Westlake Village, Calif.-based MannKind will receive an up-front payment of $45 million from the Silver Spring, Md.-based biotechnology company, which already markets a version of treprostinil in the U.S. as Tyvaso.

Tyvaso generated $372.9 million in revenue in 2017, down 7.8% year over year.